STAM

Across TCGA pan-cancer cohorts, STAM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STAM data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher STAM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STAM expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where STAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.324	0.938	<.001	26	view →
HNSC	OS	Median	All	1.000	0.449	.023	6	view →
LUAD	OS	Median	II,III,IV	0.462	0.874	.034	4	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
CCRCC	OS	Median	All	0.947	0.849	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STAM–LSCC (DFS)

Open the LSCC breakdown →